江苏四环生物股份有限公司 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 6 - 0 5 号 关于公司股票可能被终止上市的第四次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。若 公司出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 2、根据《股票上市规则》第 9.3.6 条的规定：上市公司因触及本规则第 9.3.1 条第一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当在其股 票交易被实施退市风险警示当年会计年度结束后一个月内，披露股票可能被终止 上市的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每十个交 易日披露 ...

1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司 2024 年度经审计的净利润为负值且营业收入低于 3 亿元， 根据《股票上市规则》第 9.3.1 条第一款第一项之规定，公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。 2、根据《股票上市规则》第 9.3.6 条的规定：公司因触及本规则第 9.3.1 条第一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当分别在 年度报告预约披露日前二十个交易日和十个交易日，披露年度报告编制及最新审 计进展情况。 公司 2025 年年度报告的预约披露日期为 2026 年 4 月 18 日，现将公司 2025 年年度报告编制及最新审计进展情况公告如下： 一、2025 年年度报告编制及最新审计进展情况 1、审计机构中审亚太会计师事务所（特殊普通合伙）（以下简称"中审亚 太"）项目组自进驻公司现场审计工作以来，已与公司董事会审计委员会、管理 层就审计计划、审计范围、时间安排和关键审计事项等重要事项进行了沟通。 股 票 代 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 6 - 0 4 号 江苏四环生物股份有限公司 关于公司股票可能被终止上市的第三次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。若 公司出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 一、公司股票可能被终止上市的原因 2025 年 4 月 29 日，公司披露了《关于公司股票交易被实行退市风险警示暨 停牌的公告》（公告编号：临-2025-24 号）。根据 2024 年度审计报告，公司 2024 年度经审计的净利润为负值且营业收入低于 3 亿元，根据《股票上市规则》第 9.3.1 条第一款第一 ...

Core Viewpoint - ST Siuhuan (stock code: 000518) is facing delisting risk due to its 2024 financial performance, which has triggered a warning. If the audited financial data for 2025 also fails to meet the required standards, the company's stock may be terminated from listing [1][2]. Recent Events - ST Siuhuan has been placed under delisting risk warning as of January 27, 2026, due to a negative net profit for 2024 and revenue below 300 million yuan. The delisting risk warning will be updated every ten trading days, and investors are advised to monitor subsequent announcements closely [1]. - The stock price of ST Siuhuan has shown a downward trend over the past week (February 6 to February 12, 2026), with a closing price drop from 2.61 yuan to 2.55 yuan, reflecting a cumulative decline of approximately 2.3%. The stock experienced a single-day drop of 1.92% on February 12, with a trading volume of 22.39 million yuan and a turnover rate of 0.85% [1]. Financial Report Analysis - The 2025 performance forecast indicates an expected net loss of 30 million to 40 million yuan, with a non-recurring net profit loss of 33 million to 46 million yuan, and revenue projected between 340 million and 360 million yuan. The primary reasons for the losses include increased sales revenue from subsidiaries and cost control issues, while overall profitability remains under pressure [2]. - The internal control audit for 2024 received a negative opinion, further compounding the company's fundamental challenges alongside the delisting risk [2].

Core Viewpoint - Jiangsu Sihuan Biological Co., Ltd. is facing a risk of being delisted due to negative net profit and insufficient revenue as per the Shenzhen Stock Exchange regulations [2][3]. Group 1: Delisting Risk Announcement - The company announced on April 29, 2025, that its stock would be subject to delisting risk warning starting April 30, 2025, due to a negative net profit and revenue below 300 million yuan for the fiscal year 2024 [2][3]. - According to the Shenzhen Stock Exchange's listing rules, if the company continues to meet the criteria for delisting in the following fiscal year, its stock may be terminated from listing [3][11]. Group 2: Financial Performance Indicators - The audited net profit for the fiscal year 2024 was reported as negative, and the operating revenue was below 300 million yuan, triggering the delisting risk warning [3][4]. - The company projected a net profit (excluding non-recurring gains and losses) for 2025 to be between -46 million yuan and -33 million yuan, with expected operating revenue between 330 million yuan and 350 million yuan [11]. Group 3: Compliance and Disclosure Obligations - The company is required to disclose risk warning announcements every ten trading days until the annual report is released, following the initial risk warning announcement [2][11]. - The company will adhere to the information disclosure obligations as stipulated by the Shenzhen Stock Exchange, with designated media for announcements including Securities Times and China Securities Journal [11].

关于公司股票可能被终止上市的第二次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。若 公司出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 6 - 0 3 号 江苏四环生物股份有限公司 2、根据《股票上市规则》第 9.3.6 条的规定：上市公司因触及本规则第 9.3.1 条第一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当在其股 票交易被实施退市风险警示当年会计年度结束后一个月内，披露股票可能被终止 上市的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每十个交 易日披露 ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Core Viewpoint - The company, Jiangsu Sihuan Bioengineering Co., Ltd., is expected to report a negative net profit for the fiscal year 2025, following a financial warning due to previous losses and low revenue [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a net profit in the range of -46 million to -33 million yuan, with revenue expected to be between 330 million and 350 million yuan [4][18]. - The forecast data is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm [2][5]. Group 2: Reasons for Performance Changes - The increase in revenue is primarily attributed to significant growth in seedling sales from the wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd. [3]. - The reduction in net losses is due to decreased asset impairment losses and operating expenses, as well as improved cost control by the subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd. [3]. Group 3: Risk of Delisting - The company's stock will be subject to delisting risk warnings starting April 30, 2025, due to a negative audited net profit and revenue below 300 million yuan for the fiscal year 2024 [4][10]. - If the company fails to meet certain financial criteria in the 2025 annual report, it may face termination of its stock listing [10][17].

Core Viewpoint - *ST SiHuan (000518.SZ) expects a net profit attributable to shareholders of the listed company to be between -40 million to -30 million yuan for the year 2025, with a net profit after deducting non-recurring gains and losses projected to be between -46 million to -33 million yuan [1] Group 1: Financial Performance - The company's revenue growth is primarily attributed to a significant increase in seedling sales from its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd. [1] - The reduction in net loss year-on-year is mainly due to decreased asset impairment losses and operating expenses, as well as improved cost control measures by its controlling subsidiary, Beijing SiHuan Biological Pharmaceutical Co., Ltd. [1]

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 6 - 0 2 号 江苏四环生物股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号：临 -2025-24 号），公司股票自 2025 年 4 月 30 日开市起被实施退市风险警示。若 公司出现《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"） 第 9.3.12 条规定的情形，公司股票存在被终止上市的风险。 2、根据《股票上市规则》第 9.3.6 条"上市公司因触及本规则第 9.3.1 条 第一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当在其股票 交易被实施退市风险警示当年会计年度结束后一个月内，披露股票可能被终止上 市的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每十个交易 日披露一次风险提 ...